Comparative Pharmacology
Head-to-head clinical analysis: ENFLONSIA versus FORANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENFLONSIA versus FORANE.
ENFLONSIA vs FORANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENFLONSIA is a synthetic opioid that acts as a full agonist at mu-opioid receptors, producing analgesia, sedation, and euphoria. It also has weak activity at kappa and delta opioid receptors.
Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.
10 mg orally twice daily for 12 weeks; if tolerated and response inadequate, may increase to 20 mg twice daily.
Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.
None Documented
None Documented
Terminal half-life 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment.
Context-sensitive half-life: 2-5 minutes after short exposure; prolonged to 30-60 minutes after prolonged administration due to accumulation in fat and muscle. Terminal elimination half-life: 0.5-1 hour.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal elimination as metabolites.
Primarily exhaled unchanged via lungs (>95%); <5% metabolized in liver to fluoride ions and other metabolites, which are excreted renally.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic